Ginkgo Bioworks Holdings (DNA) Receivables - Other (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Receivables - Other data on file, last reported at $11.4 million in Q1 2026.

• Quarterly Receivables - Other changed N/A year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.4 million (changed N/A YoY) and the FY2025 annual result came in at $14.5 million, up 28.32% from the prior year.
• Receivables - Other slipped to $11.4 million in Q1 2026, from $14.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $14.5 million in Q4 2025 to a low of $1.6 million in Q1 2023.
• A 5-year average of $8.9 million and a median of $10.4 million in 2023 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2022 — Receivables - Other soared 2066.67% — and 2023, when it slumped 58.47%.
• Tracing DNA's Receivables - Other over 5 years: stood at $6.2 million in 2022, then jumped by 63.51% to $10.1 million in 2023, then gained by 11.88% to $11.3 million in 2024, then advanced by 28.32% to $14.5 million in 2025, then retreated by 21.38% to $11.4 million in 2026.
• The last three Receivables - Other figures came in at $11.4 million (Q1 2026), $14.5 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.